-
Something wrong with this record ?
The Periphery of Salivary Gland Carcinoma Tumors Reveals a PD-L1/PD-1 Biomarker Niche for the Evaluation of Disease Severity and Tumor-Immune System Interplay
M. Kuchar, Z. Strizova, L. Capkova, M. Komarc, J. Skrivan, J. Bartunkova, D. Smrz, J. Plzak
Language English Country Switzerland
Document type Journal Article
Grant support
GA UK No. 364218 and PRIMUS/MED/12
Charles University
AZV 16-28135A
Ministry of Health, Czech Republic
Progres Q28
Charles University, First Faculty of Medicine
NLK
Directory of Open Access Journals
from 2013
PubMed Central
from 2013
Europe PubMed Central
from 2013
ProQuest Central
from 2013-01-01
Open Access Digital Library
from 2013-01-01
ROAD: Directory of Open Access Scholarly Resources
from 2013
- Publication type
- Journal Article MeSH
The treatment options for patients with advanced salivary gland cancers (SGCs) are limited. Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment. However, the response to ICI immunotherapy is largely driven by the immune cell signatures within the tumor tissue and the para-tumoral tissue compartments. To date, there are no data on the expression of programed cell death protein-1/programed cell death protein-ligand 1 (PD-1/PD-L1) in SGC, which may enable the implementation of ICI immunotherapy for this disease. Thus, we performed an immunohistochemical analysis of PD-1 and PD-L1 expression in tumor cells and tumor-infiltrating immune cells (TIICs) in the tumor center and periphery of 62 SGC patients. The tumor periphery showed significantly higher expression of PD-L1 in tumor cells than in TIICs. Moreover, peripheral TIICs had significantly higher PD-1 expression than peripheral tumor cells. PD-1-positive tumor cells were detected exclusively in the tumor center of high-grade tumors, and most importantly, the presence of lymph node (LN) metastases and primary tumor stage significantly correlated with the presence of PD-L1-positive tumor cells in the tumor periphery. The PD-1/PD-L1 molecular signatures in SGC are clustered predominantly in the tumor periphery, reflect disease severity, and may predict the response to ICI immunotherapy in SGC patients.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21010639
- 003
- CZ-PrNML
- 005
- 20210610095712.0
- 007
- ta
- 008
- 210413s2021 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3390/biomedicines9020097 $2 doi
- 035 __
- $a (PubMed)33498270
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Kuchar, Martin $u Department of Otorhinolaryngology and Head and Neck Surgery, First Faculty of Medicine, Charles University and University Hospital Motol, 15006 Prague, Czech Republic
- 245 14
- $a The Periphery of Salivary Gland Carcinoma Tumors Reveals a PD-L1/PD-1 Biomarker Niche for the Evaluation of Disease Severity and Tumor-Immune System Interplay / $c M. Kuchar, Z. Strizova, L. Capkova, M. Komarc, J. Skrivan, J. Bartunkova, D. Smrz, J. Plzak
- 520 9_
- $a The treatment options for patients with advanced salivary gland cancers (SGCs) are limited. Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment. However, the response to ICI immunotherapy is largely driven by the immune cell signatures within the tumor tissue and the para-tumoral tissue compartments. To date, there are no data on the expression of programed cell death protein-1/programed cell death protein-ligand 1 (PD-1/PD-L1) in SGC, which may enable the implementation of ICI immunotherapy for this disease. Thus, we performed an immunohistochemical analysis of PD-1 and PD-L1 expression in tumor cells and tumor-infiltrating immune cells (TIICs) in the tumor center and periphery of 62 SGC patients. The tumor periphery showed significantly higher expression of PD-L1 in tumor cells than in TIICs. Moreover, peripheral TIICs had significantly higher PD-1 expression than peripheral tumor cells. PD-1-positive tumor cells were detected exclusively in the tumor center of high-grade tumors, and most importantly, the presence of lymph node (LN) metastases and primary tumor stage significantly correlated with the presence of PD-L1-positive tumor cells in the tumor periphery. The PD-1/PD-L1 molecular signatures in SGC are clustered predominantly in the tumor periphery, reflect disease severity, and may predict the response to ICI immunotherapy in SGC patients.
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Strizova, Zuzana $u Department of Immunology, Second Faculty of Medicine, Charles University and University Hospital Motol, 15006 Prague, Czech Republic
- 700 1_
- $a Capkova, Linda $u Department of Pathology and Molecular Medicine, Second Faculty of Medicine, Charles University and University Hospital Motol, 15006 Prague, Czech Republic
- 700 1_
- $a Komarc, Martin $u Department of Methodology, Faculty of Physical Education and Sport, Charles University, 16252 Prague, Czech Republic
- 700 1_
- $a Skrivan, Jiri $u Department of Otorhinolaryngology, Second Faculty of Medicine, Charles University and University Hospital Motol, 15006 Prague, Czech Republic
- 700 1_
- $a Bartunkova, Jirina $u Department of Immunology, Second Faculty of Medicine, Charles University and University Hospital Motol, 15006 Prague, Czech Republic
- 700 1_
- $a Smrz, Daniel $u Department of Immunology, Second Faculty of Medicine, Charles University and University Hospital Motol, 15006 Prague, Czech Republic
- 700 1_
- $a Plzak, Jan $u Department of Otorhinolaryngology and Head and Neck Surgery, First Faculty of Medicine, Charles University and University Hospital Motol, 15006 Prague, Czech Republic
- 773 0_
- $w MED00205373 $t Biomedicines $x 2227-9059 $g Roč. 9, č. 2 (2021)
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/33498270 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20210413 $b ABA008
- 991 __
- $a 20210610095712 $b ABA008
- 999 __
- $a ind $b bmc $g 1649889 $s 1131015
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 9 $c 2 $e 20210120 $i 2227-9059 $m Biomedicines $n Biomedicines $x MED00205373
- GRA __
- $a GA UK No. 364218 and PRIMUS/MED/12 $p Charles University
- GRA __
- $a AZV 16-28135A $p Ministry of Health, Czech Republic
- GRA __
- $a Progres Q28 $p Charles University, First Faculty of Medicine
- LZP __
- $a Pubmed-20210413
